Revlimid lenalidomide regulatory update

Japan's Ministry of Health, Labor and Welfare approved Revlimid lenalidomide from Celgene to treat myelodysplastic syndrome (MDS) in patients with 5q chromosomal deletion. In June, Japan approved the ...